Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CAR-T Cells in R/R B-ALL
NCT03574168Phase 1Unknown
- Sponsor
- Bioceltech Therapeutics, Ltd.
- Start
- Jul 2018
- Primary completion
- Dec 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19-CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Bioceltech Therapeutics, Ltd. Primary endpoint: Objective Response Rate at Day 90. Status: unknown.
02
Drugs
CD19-CAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03574168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03574168.